CJEU puts further brakes on SPCs
Brian A Jackson / Shutterstock.com
The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
At the end of April the Court of Justice of the European Union (CJEU) delivered its judgment in Case C-650/17 Royalty Pharma Collection Trust.
The decision relates to yet another preliminary reference to the CJEU on the interpretation of article 3(a) of the Supplementary Protection Certificate (SPC) Regulation and is the second time the CJEU has been given the opportunity to clarify what the test should be for functional claims.
While the decision includes some welcome clarity, it is also mixed with several new elements of ambiguity which no doubt will keep attorneys, patent offices and courts scratching their heads for some time to come.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CJEU, Court of Justice of the European Union, SPC, supplementary protection certificates, Royalty Pharma, Beatriz San Martin, Arnold & Porter